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Abstract 
Review on 6p deletion in myeloid malignancies. The 
neighbor genes JARID2 and DTNBP1: possible 
relation and clinical relevance. 
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Clinics and pathology 
The deletion of 6p as isolated anomaly in the 
karyotype is a very rare event in myeloid disorders. 
To date only 16 cases have been reported: 2 cases 
with myelodysplastic syndrome (MDS), 3 cases with 
myeloproliferative neoplasms (MPN) and 11 cases 
with acute myeloid leukemia (AML). The anomaly 
was determined by conventional cytogenetics 
predominantly as terminal deletion (11 cases) and 
more rarely as interstitial deletion. The terminal 
deletions affected most frequently the region 6p23-
6pter (7 cases), while the interstitial deletions 
occurred between the bands 6p12 and 6p25 and the 
deleted segments are variable in size. 
Disease 
Acute myeloid leukemia 
Epidemiology 
The deletion of 6p is found in 11 cases with AML ( 
0.06 % of all AML cases with an abnormal 
karyotype): 1 case with M1 French-American- 
British (FAB) phenotype (Morris and Fitzgerald, 
1985), 5 cases with M2 (Golomb et al, 1978; 
Yamasaki et al, 1996; Voskova et al, 2004; Igbal et 
al, 2006), 1 case with M3 (Nakase et al, 2000), 1 case 
with M4 (Haase et al, 1995) and 3 cases with AML-
NOS (Clavio et al, 2001; Kern et al, 2002; Stark et 
al, 2004). The sex ratio is balanced M:F=1.2:1. The 
age is documented in 6 cases: 20, 35, 53 (M2), 70 
(M3), 73 (M4) and 52 (AML-NOS). The average age 
is 52.6 year (range 20-73). 
Cytogenetics 
Six cases are with terminal deletions with 
breakpoints located respectively in 6p21 (1 case), 
6p22 (1 case), and 6p23 (4 cases). Three cases are 
presented with interstitial deletions and the deleted 
segments are variable in size (6p21-23, 6p21-25 and 
6p12-23). In two cases the clones with 6p- are 
associated with unrelated clones carrying other 
cytogenetic anomalies including inv(3)(q21q26), 
del(7q), +8 and +13. In one case is found a secondary 




Two cases with terminal deletions del(6)(p23) are 
reported: one (76-year- old male) with idiopathic 
myelofibrosis (Reilly et al, 1997) and another with 




Three cases are described: two cases (3 and 62-year-
old-female) with MDS-MOS (GFCH, 1988; Chen et 
al, 2000) and one case (62-year-old female) with 
RAEB-2 (Refractory anaemia with excess blasts) 
(Meloni-Ehrig et al, 2010). 
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Cytogenetics 
Two cases are with interstitial deletions 
del(6)(p22p25) and del(6)(p23p25) and one with a 
terminal deletion del(6)(p21). The 6p- in one case is 
associated with constitutional +21 and in another 
with t(9;22)(q34;q11)in a secondary clone. 
Genes involved and 
proteins 
Inactivation of a tumor suppressor gene(s) (TSG) 
as a result of a 6p deletion is possibly linked to the 
molecular pathogenesis of the 6p- anomaly. In the 
region 6p12-25 where the deletions have been 
observed a number of genes are identified that may 
act as putative TSG, including CDKN1A (6p21.2) 
FKBP5 (6p21.31), DAXX (6p21.32), MHC class I 
genes, MPC1, TRIM27 (6p22.1), CASC15, ID4, 
JARID2 (6p22.3), NOL7 (6p23), DUSP22 (6p25.3). 
Almost all of them are involved in the pathogenesis 
of different solid tumors. The minimal deleted 
region(s) (MDR) at 6p reported in 
myeloproliferative disorders may point out which of 
these genes possibly play a role in 6p- associated 
myeloid malignances. Using high-resolution SNP 
microarrays, Puda et al, 2012 provided evidence that 
a region of 1.1Mb containing only the JARID2 gene 
- member of the polycomb repressive complex 2 
(PRC2) is frequently deleted during leukemic 
transformation of chronic myeloid malignances 
(MDS and MPN).Three additional MDRs at 6p have 
been found with high-resolution genotyping in a 
large series of secondary AML by Milosevic et al, 
2012. One of these regions (6p22.3:14130000-
1580000) also co-insides with the genome location 
of the JARID2 gene (6p22.3:15245975-15522042). 
Both studies indicated that JARID2 gene is involved 
as a TSG in the pathogenesis of the 6p- associated 
myeloid malignances. In the cases in which larger 
segments are deleted than the MDR where JARID2 
is mapped, involvement of other genes in the 
pathogenesis of 6p- associated myeloid malignances, 
especially those that have been shown to play a role 
in oncohematological diseases (CASC15, ID4 and 
DUSP22) (Contreras et al., 2016; Zhou et al., 2017; 
Melard et al., 2016), can also be assumed.  
JARID2 and DTNBP1 in close proximity: It is 
interesting to note that JARID2 is located in very 
close proximity to the DTNBP1 gene (Dysbindin) 
(genome location chr 6: 15522801-15663058). The 
distance between JARID2 and DTNBP1 is only 759 
bp and remains constant in mammals (approximately 
1 kb). Both genes have divergent patterns of gene 
expression, conservative gene structures and are 
implicated in embryonic development and 
morphogenesis (JARID2: heart and liver 
development, neural tube formation, differentiation 
of embryonic stem cells; DTNBP1: regulation of 
dendritic spine morphogenesis and neurite 
outgrowth).These data suggest that both genes are 
with coordinate transcription and are functionally 
linked.  
The Neighbor Genes JARID2 and DTNBP1: 
Possible Relation and Clinical Relevance 
Both genes are characterized by a variety of 
functions:  
JARID2 (Jumonji, AT Rich Interaction Domain 
2) facilitates PRC2 recruitment to its target genes 
and in this way stimulates PCR2 mediated lysine 27 
di/trimethylation of histone H3 (H3K27me2/3). It is 
required for PCR2-repressive activity in different 
cell types, including in embryonic stem (ES) cells. It 
also represses the expression of CCND1 (cyclin-D1) 
by activating methylation of Lys 9 of histone H3 
(H3K9me) (trough EHMT1 (GLP1) and EHMT2 
(G9a) histone methyltransferases) and via 
interaction with GATA4 and NKX2-5 represses the 
transcription of NPPA (natriuretic peptide A).  
DTNBP1 (Dysbindin) is one of the candidate 
susceptibility genes for schizophrenia. As a 
component of the Biogenesis of Lysosome-related 
Organel Complex-1 (BLOC-1) it is required for the 
normal biogenesis of the endosomal-lysosomal 
system. It appears to promote neuronal transmission 
influencing glutamatergic release and modulates 
prefrontal cortical activity via the dopamine D2 
pathway. It is involved also in actin cytoskeleton 
reorganization, neurite outgrowth and regulation of 
cell surface exposure of DRD2. In association with 
the BLOC-2 complex it facilitates the transport of 
TYRP1 (Tyrosinase related protein 1).  
Actin cytoskeleton  
The detailed consideration of the functions of the 
two genes indicated that the merging entity, which 
possibly binds them functionally, is the actin 
cytoskeleton reorganization. In dendritic spines 
dysbindin assembles a protein complex with WASF2 
(WAVE2) and ABI1, which activates the actin 
nucleators ACTR2/ ACTR3 (ARP 2/3) enabling de 
novo rapid actin polymerization (Ito et al, 2010). 
WAVE2-Arp2/3 induced actin polymerization is 
associated with the formation of the cell 
cytoskeleton, including bundled or branched 
filamentous structures, such as filopodia and 
lamellipodia that are responsible for the cell motility 
and adhesion. On the other hand actin 
polymerization (as well as depolymerization) are 
important for the regulation of the G-actin 
homeostasis. Actin depolymerization (or its down 
regulation by decreased dysbindin expression) will 
increase the cytoplasmic G-actin (monomeric form) 
which will lead to translocation of G-actin from the 
cytoplasm to the nucleus via IPO9 (importin 9) 
(Dopie et al, 2012). In turn, the increased nuclear 
actin will enhance transcriptional activity, because it 
is a component of the transcription initiation 
complex of RNA polymerases II (Hofmann et al, 
2004) and is bound also to the heterogenous 
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rebonucleoproteins and HAT1 (histone 
acetyltransferase) during transcriptional elongation 
(Obrdlic et al, 2008). In the opposite mechanism 
increased actin polymerization (including caused by 
increased dysbindin expression) will result in a 
decreased level of nuclear G-actin and respectively 
in a decreased activity of the RNA polymerases - a 
process that would allow suppression of the gene 
transcription by polycomb 2 mediated histone H3 
lysine 27 trimetylation (Le et al, 2016). It could be 
concluded that a coordinated transcription of both 
neighbor genes JARID2 (member of the repressor 
complex of polycomb 2) and DTNBP1 are 
responsible for the transition from an active 
transcriptional status to gene repression, and that one 
of the mechanisms which possibly modulates this 
process is dysbindin expression. It seems that an 
interconnection exists between polycomb 2 complex 
and the cytoplasmic/nuclear actin axis. The fact that 
the core unit of the cytosolic polycomb 2 complex 
Ezh2 (structurally resembles the nuclear Ezh2 
complex) controlled the cytoplasmic actin 
polymerization in various cell types and human 
prostate cancer cells conforms to this assumption (Su 
et al, 2005; Bryant et al, 2008).  
The data presented above could highlight the 
genome alterations in schizophrenia, the 
mechanisms related to the high incidence of 
malignances in Wiskott-Aldrich syndrome and the 
pathogenesis of the 6p- associated 
myeloproliferative disorders. 
It has been found that schizophrenia is associated 
with both insufficiency of key regulators of actin 
polymerization as dysbindin (Weickert et al., 2004), 
Arp2/3 (Datta et al., 2016), CYFIP1 (Pathania et al., 
2014) and regulators of Rho-family GTPases (Hill et 
al., 2006; Hayashi-Takagi et al., 2010) and 
deregulation of the actin homeostasis manifested by 
increased G-actin, decreased F-actin and decreased 
ratios of F-actin/total actin as a result of reduced  
actin polymerization in the anterior cingulated cortex 
of schizophrenic patients (Bhambhvani et al., 2017). 
These findings indicated that the reduced actin 
polymerization in schizophrenia could create an 
increased level of nuclear monomeric actin leading 
to prolonged transcription of certain gene sets as a 
result of genome imbalance between activators and 
suppressors. The same genome imbalance as a 
consequence of defective actin polymerization in 
highly divided tissues, such as the hematopoietic 
tissue, could be a prerequisite for leukemogenesis. 
First, genes with prolonged transcription will be at 
risk of damage and involvement in chromosomal 
rearrangements. Second, the normal order of the 
expression of the genes will be impaired, which 
would affect the functioning of the signaling 
pathways. The noted prerequisite for 
leukemogenesis will explain the high incidence of 
malignances (including MDS and AML) in the 
Wiskott-Aldrich syndrome (Salavoura, et al., 2008), 
because this complex X-linked disorder is also 
associated with aberrant actin polymerization as a 
result of the insufficiency of the key regulator of the 
actin cytoskeleton  in the hematopoietic cells known 
as WASp.  
The pathogenesis of 6p- associated myeloid 
malignances is related with the deletion of both 
genes JARID2 and DTNBP1. JARID2 is a cofactor 
of PRC2 (polycomb repressive complex 2) 
regulating its targeting to chromatin allowing 
methylation of lysine 27 on histone H3 - a process 
that plays a very important role not only in the 
differentiation of the embryonic stem cell (evidenced 
by their impairs differentiation in its absence) 
(Landeira et al, 2010), but also in the differentiation 
of the precursor and stem cells of the hematopoietic 
system (Kinkel et al, 2015). Therefore, deletion of 
JARID2 would result in PRC2 insufficiency and 
impossibility to repress the gene set coordinating the 
function of the myeloid precursors. On the other 
hand, deletion of DTNBP1 leads to an increased 
level of nuclear monomeric actin and constant 
activation of the genes that are not suppressed by 
PRC2. In other words, the gene orchestration 
responsible for the transition of the precursor cell to 
the next stages of differentiation is compromised 
which is manifested in maturation arrest and 
accumulation of immature cells. This interpretation 
is confirmed by the fact that the locus of JARID2 
(and respectively DTNBP1) is frequently deleted 
during leukemic transformation of chronic myeloid 
malignances and that most of the cases with 6p- 
associated myeloid disorders are MDS and AML. 
However, there are indications that nuclear 
monomeric actin is also involved as JARID2 in 
differentiation of the hematopoietic system 
(macrophage-like differentiation of HL-50 cells) 
(Xu et al, 2010) and is included in the chromatin 
remodeling complex SWI/SNF (Szerlong et al, 
2008) that can function as both - transcriptional 
activator and repressor (Tolstorukov et al, 2013). It 
is possible that actin may affect genes related to the 
differentiation of the myeloid series, which would 
explain the observation that almost half of the 6p- 
associated AML are with M2 subtype (acute myeloid 
leukemia with differentiation). 
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